In exploring possible therapeutic options for CIN, researchers have found that a renal protective drug could increase the activation of the Nrf2 antioxidant defense pathway (Khaleel et al., 2017). Here, NFE2L2 is linked to cervical squamous intraepithelial neoplasia.